- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05881382
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction (HEAL-MI)
Phase 3, Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
The goal of this phase 3, randomized, double-blind, placebo-controlled clinical trial is to explore the safety and efficacy of dutogliptin administered subcutaneously (SC) in co-administration with filgrastim in adult patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
The primary objective is to evaluate the efficacy of dutogliptin compared with placebo in STEMI patients within 180 days of randomization measured by the time of first occurrence of a composite endpoint of cardiovascular (CV) death and worsening heart failure (HF) within 180 days. Participants will receive dutogliptin twice daily subcutaneously (SC) for 14 days and filgrastim (SC) daily for 5 days or placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age 18 to 85 years (having reached 18 years of age and before having reached 86 years of age at the time of ICF signing)
- Able to provide written informed consent, including signing and dating the ICF
- STEMI is defined as follows:
Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain, arm pain, diaphoresis, or any anginal equivalent) AND
Anterior STEMI:
ECG Criteria
- men > 40 years: ≥ 2 mm of new ST elevation in V2 and V3
- men ≤ 40 years: ≥ 2.5 mm of new ST elevation in V2 and V3
- women: ≥ 1.5 mm of new ST elevation in V2 and V3
ECG Criteria
o ≥ 1 mm of new ST elevation in two contiguous leads 4. STEMI must meet one of the following criteria:
- Anterior STEMI with thrombolysis in myocardial infarction (TIMI) 0 or 1 flow at presentation
Non-anterior MI with the following:
- TIMI 0 flow at presentation AND
- Signs of HF, defined as at least one of the following radiographic evidence of pulmonary congestion, peripheral edema, increased jugular venous pressure, hepatojugular reflux or both, third heart sound or gallop 6. Female patients of childbearing potential must have a negative serum pregnancy test at Screening and an additional negative urine pregnancy test prior to the first dose of IMP unless regulated differently by national legislation.
Exclusion Criteria:
- Known significant pre-existing cardiomyopathy, moderate or severe mitral disease or aortic valvular disease
- Known pre-existing left ventricular ejection fraction < 40%
- Existing heart transplant
- Treatment with any dipeptidyl peptidase 4 (DPP4) inhibitors (eg, alogliptin, lingliptin, vildagliptin, saxagliptin, sitagliptin) or granulocyte colony-stimulation factor (G-CSF) medication (eg, filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim) within 4 months prior to randomization.
- Contraindication to treatment with filgrastim, including known allergy to filgrastim or other G-CSF medication
- Pregnant, planning to become pregnant, or nursing female patients
- Known history of severe renal impairment or current renal impairment requiring dialysis
- History of pancreatitis (induced by high doses of DPP-4 inhibitors)
- Current or planned use of sulfonyl urea (risk of severe hypoglycemia)
- Any clinically significant abnormality identified prior to randomization that in the judgement of the Investigator or Sponsor that would preclude safe completion of the study, or confound the anticipated benefit of dutogliptin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dutogliptin + Filgrastim
Participants will receive BID SC injections of 60 mg dutogliptin for 14 days in co-administration with 10 µg/kg filgrastim for 5 days.
|
dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
|
Placebo Comparator: Placebo-Dutogliptin + Placebo-Filgrastim
Randomized participants will receive BID SC injections of dutogliptin placebo for 14 days in co-administration with filgrastim placebo for 5 days.
|
Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of first occurence of the following composite endpoint of cardiovascular (CV) death and worsening of heart failure (HF)
Time Frame: within 180 days of randomization
|
defined as either an unplanned hospitalization or urgent visit resulting in intravenous therapy for heart failure
|
within 180 days of randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Worsening heart failure
Time Frame: within 180 days of randomization
|
defined as either an unplanned hospitalization or urgent visit resulting in intravenous therapy for heart failure
|
within 180 days of randomization
|
Time to cardiovascular death
Time Frame: within 180 days of randomization
|
defined as the time from randomization to the date of cardiovascular death
|
within 180 days of randomization
|
Total symptom score of the Kansas City Cardiomyopathy Questionnaire
Time Frame: at 180 days
|
at 180 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REC-DUT-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST Elevation Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Jinan Central HospitalUnknownST-Segment Elevation Myocardial InfarctionChina
Clinical Trials on Dutogliptin + Filgrastim
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
PhenomixForest LaboratoriesTerminatedType 2 Diabetes Mellitus | Type 2 DiabetesUnited States, Malaysia, Peru, India, Argentina, Philippines, Romania, Ukraine
-
Forest LaboratoriesPhenomixTerminatedDiabetes Mellitus, Type IIUnited States, Belarus, India, Romania, Germany, Lithuania
-
PhenomixTerminatedType 2 Diabetes MellitusUnited States, Argentina, Canada, Mexico, India
-
PhenomixForest LaboratoriesTerminatedType 2 Diabetes MellitusUnited States, Argentina, Chile, Czech Republic, India, Peru, Poland
-
PhenomixForest LaboratoriesCompletedType 2 Diabetes MellitusUnited States, Ukraine, Argentina, Malaysia, India, Romania, Thailand, Philippines, Peru
-
Forest LaboratoriesPhenomixTerminatedDiabetes Mellitus, Type IIUnited States, Belarus, Colombia, Hungary, India, Lithuania, Peru, Romania
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedNon-Hodgkin's Lymphoma | Plasma Cell MyelomaUnited States
-
Franziska WachterHarvard Clinical and Translational Science Center (Harvard Catalyst)RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure SyndromeUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States